T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.36% |
| 2 | Healthcare | 16.09% |
| 3 | Consumer Discretionary | 15.79% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
926
Halozyme
HALO
$11.4B
| $62.5M | 0.01% |
1,554,544
+39,576
| +3% | +$1.48M |
|
927
Louisiana-Pacific
LPX
$5.18B
| $61.9M | 0.01% |
790,386
+36,298
| +5% | +$2.49M |
|
928
Globus Medical
GMED
$11.5B
| $61.9M | 0.01% |
857,238
-15,755
| -2% | -$1.14M |
|
929
Ryan Specialty Holdings
RYAN
$11B
| $61.9M | 0.01% |
1,533,794
+33,961
| +2% | +$1.29M |
|
930
iRhythm Holdings
IRTC
$4.06B
| $61.7M | 0.01% |
524,505
+182,413
| +53% | +$16.7M |
|
931
General Mills
GIS
$20.8B
| $61.7M | 0.01% |
916,020
-47,595
| -5% | -$3.02M |
|
932
Red Rock Resorts
RRR
$3.67B
| $61.7M | 0.01% |
1,121,859
+621,389
| +124% | +$32.3M |
|
933
LGI Homes
LGIH
$1.37B
| $61.7M | 0.01% |
399,386
+253
| +0.1% | +$37K |
|
934
SL Green Realty
SLG
$4.08B
| $61.5M | 0.01% |
831,770
-102,760
| -11% | -$7.56M |
|
|
NEX
935
DELISTED
NexTier Oilfield Solutions Inc.
NEX
| $61.3M | 0.01% |
17,273,895
-816,325
| -5% | -$3.42M |
|
936
Quanterix
QTRX
$135M
| $61.3M | 0.01% |
1,445,602
+21,554
| +2% | +$1.01M |
|
|
GBIO
937
DELISTED
Generation Bio
GBIO
| $61.2M | 0.01% |
864,712
+1,890
| +0.2% | +$330K |
|
938
Fair Isaac
FICO
$24B
| $60.8M | 0.01% |
140,291
-5,094
| -4% | -$2.02M |
|
939
Ametek
AME
$58.7B
| $60.5M | 0.01% |
411,469
-13,830
| -3% | -$1.89M |
|
940
Watts Water Technologies
WTS
$12.8B
| $60.4M | 0.01% |
310,862
+63,798
| +26% | +$12.1M |
|
|
SAGE
941
DELISTED
Sage Therapeutics
SAGE
| $60.3M | 0.01% |
1,416,522
+9,633
| +0.7% | +$403K |
|
942
Franklin Resources
BEN
$17.2B
| $59.9M | 0.01% |
1,789,528
-739,131
| -29% | -$24.3M |
|
943
Texas Roadhouse
TXRH
$13.6B
| $59.7M | 0.01% |
669,206
-254,161
| -28% | -$22.6M |
|
|
TWKS
944
DELISTED
Thoughtworks Holding, Inc. Common Stock
TWKS
| $59.6M | 0.01% |
2,222,993
-277,922
| -11% | -$7.93M |
|
945
Aflac
AFL
$60.7B
| $59.5M | 0.01% |
1,019,679
-54,068
| -5% | -$3.03M |
|
946
Braze
BRZE
$3.36B
| $59.5M | 0.01% |
+771,589
| New | +$56M |
|
|
THR
947
DELISTED
Thermon Group Holdings
THR
| $59.3M | 0.01% |
3,502,689
-17,708
| -0.5% | -$310K |
|
948
CorVel
CRVL
$3.25B
| $59M | 0.01% |
850,575
-109,983
| -11% | -$6.91M |
|
|
CVET
949
DELISTED
Covetrus, Inc. Common Stock
CVET
| $58.8M | 0.01% |
2,942,196
-2,313,781
| -44% | -$43.6M |
|
950
Comfort Systems
FIX
$60.8B
| $57.9M | 0.01% |
584,782
-16,250
| -3% | -$1.5M |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.